Corcept TherapeuticsCORT
CORT
About: Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol.
Employees: 352
0
Funds holding %
of 7,425 funds
0
Analysts bullish %
of 4 analysts
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
176% more first-time investments, than exits
New positions opened: 80 | Existing positions closed: 29
14% more funds holding
Funds holding: 317 [Q3] → 362 (+45) [Q4]
5% more capital invested
Capital invested by funds: $4.03B [Q3] → $4.24B (+$211M) [Q4]
3% less repeat investments, than reductions
Existing positions increased: 116 | Existing positions reduced: 120
3.02% less ownership
Funds ownership: 83.4% [Q3] → 80.38% (-3.02%) [Q4]
21% less call options, than puts
Call options by funds: $58.4M | Put options by funds: $73.7M
29% less funds holding in top 10
Funds holding in top 10: 7 [Q3] → 5 (-2) [Q4]
Research analyst outlook
4 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$131
82%
upside
Avg. target
$143
99%
upside
High target
$150
109%
upside
4 analyst ratings
4 positive
100%
0 neutral
0%
0 negative
0%
Piper Sandler David Amsellem 56% 1-year accuracy 18 / 32 met price target | 82%upside $131 | Overweight Maintained | 3 Apr 2025 |
Canaccord Genuity Edward Nash 65% 1-year accuracy 13 / 20 met price target | 98%upside $142 | Buy Maintained | 1 Apr 2025 |
Truist Securities Joon Lee 48% 1-year accuracy 20 / 42 met price target | 109%upside $150 | Buy Maintained | 31 Mar 2025 |
HC Wainwright & Co. Swayampakula Ramakanth 30% 1-year accuracy 57 / 192 met price target | 109%upside $150 | Buy Maintained | 31 Mar 2025 |
Financial journalist opinion
Based on 13 articles about CORT published over the past 30 days
Neutral
Business Wire
2 days ago
CORCEPT THERAPEUTICS TO ANNOUNCE FIRST QUARTER FINANCIAL RESULTS, PROVIDE CORPORATE UPDATE AND HOST CONFERENCE CALL
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report first quarter financial results and provide a corporate update on May 5, 2025. The company will also host a conference call that day at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time). Conference Call Information Participants must register in advance of the conference call by clicking here. Upon registering, each participant will receive a dial-in number and a unique access PIN.
Neutral
Business Wire
1 week ago
CORCEPT TO PRESENT LATE-BREAKING DATA FROM PIVOTAL PHASE 3 ROSELLA TRIAL OF RELACORILANT IN PLATINUM-RESISTANT OVARIAN CANCER AT ASCO 2025
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, will present data from its pivotal Phase 3 ROSELLA trial of relacorilant plus nab-paclitaxel in patients with platinum-resistant ovarian cancer at the 2025 American Society of Clinical Oncology (ASC.
Positive
Seeking Alpha
1 week ago
Corcept: Maintaining Strong Buy Even After 4Q Revenue And Earnings Miss
Despite a Q4 revenue miss, Corcept's 2025 revenue still grew 40% to $675 million, and management provided strong guidance for 2025 and beyond, projecting up to $5 billion in revenue. Corcept's potential patient population has expanded significantly from 10,000 to over 1 million in the past year, and has promising drugs in the pipeline, making it a strong acquisition target. The company announced positive trial results for an ovarian cancer medication, opening an entirely new revenue stream.
Neutral
Business Wire
1 week ago
Diabetes Care Publishes Results From Prevalence Phase Of Corcept's CATALYST Trial In People With Difficult-To-Control Type 2 Diabetes
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced the publication of findings from the prevalence phase of the CATALYST trial in Diabetes Care, a peer-reviewed journal published by the American Diabetes Association. The publication,.
Positive
Seeking Alpha
2 weeks ago
It's Still Early For Corcept: With Multiple Growth Opportunities Ahead, It's No Longer Just A One Drug Wonder
Corcept is transitioning from a single-product company to a multi-product, multi-market Platform Growth™ company, promising rapid revenue and earnings growth. Relacorilant's success in platinum-resistant ovarian cancer and potential FDA approval for hypercortisolism could significantly boost Corcept's market presence and revenue. Corcept's expanding pipeline includes promising treatments for prostate cancer, ALS, MASH, and resistant hypertension, diversifying its product portfolio and reducing investor risk.
Negative
MarketBeat
2 weeks ago
3 Biopharmaceutical Stocks Bucking the Sell-Off
With tariffs sending markets reeling in the first days of the second quarter—the S&P 500 dropped roughly 10% in the five trading periods through Apr. 7, 2025—investors with cash to spend might be looking for an opportunity. While it's true that some of the biggest firms in the world started April with major share price discounts, investors may want to find companies to target that have been more or less bulletproof in the extreme uncertainty characterizing the market.
Neutral
Business Wire
3 weeks ago
Corcept Initiates Trial of Relacorilant Plus Nab-Paclitaxel and Bevacizumab in Patients With Platinum-Resistant Ovarian Cancer
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced the start of BELLA, a Phase 2 trial of relacorilant plus nab-paclitaxel and bevacizumab evaluating efficacy and safety in patients with platinum-resistant ovarian cancer. BELLA is a.
Positive
Zacks Investment Research
4 weeks ago
Does Corcept (CORT) Have the Potential to Rally 28.63% as Wall Street Analysts Expect?
The average of price targets set by Wall Street analysts indicates a potential upside of 28.6% in Corcept (CORT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Positive
Seeking Alpha
4 weeks ago
Corcept Therapeutics: New PROC SOC Treatment Option With Relacorilant Data Release
Corcept Therapeutics Incorporated's relacorilant met the primary endpoint in the phase 3 ROSELLA study for platinum-resistant ovarian cancer patients, boosting shares by over 90% the very same day. Upcoming catalysts include full trial data release at a medical conference, NDA filing in Q3 2025, and MAA submission to the EMA shortly afterward. Relacorilant also targets hypercortisolism with endogenous Cushing's Syndrome patients with an FDA PDUFA date set for December 30, 2025, based on positive GRACE, GRADIENT, and phase 2 study data.
Positive
Zacks Investment Research
4 weeks ago
CORT Shares Rise as Relacorilant Combo Meets Ovarian Cancer Study Goal
The ROSELLA study evaluating Corcept's relacorilant plus nab-paclitaxel for treating patients with platinum-resistant ovarian cancer meets the primary endpoint.
Charts implemented using Lightweight Charts™